Cladribine 2-CdA immunosuppressant data

Results of a Phase III trial in 48 patients with chronic progressive multiple sclerosis were published in The Lancet, showing improvement after administration of the nucleoside cladribine (2-chlorodeoxyadenosine).

Average neurologic scores, volume of lesions on MRI, and immune indices in the spinal fluid all remained stable or improved in treated patients, but continued to decline in those given placebo. Neurologic scores, as measured by two indices, were significantly improved (p<0.004 and 0.001). ...